Anebulo reports positive Phase 2 results for ANEB-001 reversing THC effects

Anebulo Pharmaceuticals, Inc.

Low 10 mg dose of ANEB-001 given 1 hour after THC rapidly reversed psychotropic effects (VAS feeling high p<0.0001).
Pre-specified pooled analysis at 21/30 mg THC showed significance on all primary outcomes (p<0.02 for each).
ANEB-001 was well tolerated; no serious adverse events; mild to moderate THC symptoms observed before dosing.
High-fat meal blunted THC effects, but 10 mg ANEB-001 still significantly reduced VAS feeling high (p=0.003).
Company expects End of Phase 2A meeting with FDA by mid-2023 to discuss path forward.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.